Tredje AP fonden Buys 1,241 Shares of United Therapeutics Corporation $UTHR

Tredje AP fonden grew its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 28.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,561 shares of the biotechnology company’s stock after purchasing an additional 1,241 shares during the period. Tredje AP fonden’s holdings in United Therapeutics were worth $2,710,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Torren Management LLC purchased a new stake in United Therapeutics in the 4th quarter worth approximately $26,000. Activest Wealth Management raised its holdings in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares in the last quarter. WealthCollab LLC raised its holdings in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the period. Finally, Entrust Financial LLC bought a new stake in United Therapeutics in the fourth quarter valued at $31,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

UTHR has been the topic of several recent research reports. UBS Group upped their price target on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. TD Cowen upped their target price on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a research note on Monday, March 30th. Royal Bank Of Canada reduced their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Oppenheimer upped their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Finally, Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $619.42.

Insiders Place Their Bets

In other news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $9,956,712.48. The trade was a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Michael Benkowitz sold 14,440 shares of the company’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $472.13, for a total transaction of $6,817,557.20. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 550,413 shares of company stock valued at $305,867,937. 8.60% of the stock is owned by company insiders.

United Therapeutics Trading Down 0.0%

Shares of United Therapeutics stock opened at $566.80 on Wednesday. The firm has a market cap of $24.06 billion, a PE ratio of 20.92, a PEG ratio of 1.83 and a beta of 0.60. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The stock has a 50 day moving average of $561.48 and a 200 day moving average of $509.54.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the previous year, the business earned $6.63 EPS. As a group, equities research analysts forecast that United Therapeutics Corporation will post 27.07 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.